Skip to main content
Erschienen in: World Journal of Surgical Oncology 1/2018

Open Access 01.12.2018 | Research

Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR

verfasst von: Yue-ya Liang, Jia-cheng Huang, Rui-xue Tang, Wen-jie Chen, Peng Chen, Wei-luan Cen, Ke Shi, Li Gao, Xiang Gao, An-gui Liu, Xiao-tong Peng, Gang Chen, Su-ning Huang, Ye-ying Fang, Yong-yao Gu

Erschienen in: World Journal of Surgical Oncology | Ausgabe 1/2018

Abstract

Background

To examine the clinical value of miR-198-5p in lung squamous cell carcinoma (LUSC).

Methods

Gene Expression Omnibus (GEO) microarray datasets were used to explore the miR-198-5p expression and its diagnostic value in LUSC. Real-time reverse transcription quantitative polymerase chain reaction was used to evaluate the expression of miR-198-5p in 23 formalin-fixed, paraffin-embedded (FFPE) LUSC tissues and corresponding non-cancerous tissues. The correlation between miR-198-5p expression and clinic pathological features was assessed. Meanwhile, putative target messenger RNAs of miR-198-5p were identified based on the analysis of differentially expressed genes in the Cancer Genome Atlas (TCGA) and 12 miRNA prediction tools. Subsequently, the putative target genes were sent to Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses.

Results

MiR-198-5p was low expressed in LUSC tissues. The combined standard mean difference (SMD) values of miR-198-5p expression based on GEO datasets were − 0.30 (95% confidence interval (CI) − 0.54, − 0.06) and − 0.39 (95% CI − 0.83, 0.05) using fixed effect model and random effect model, respectively. The sensitivity and specificity were not sufficiently high, as the area under the curve (AUC) was 0.7749 (Q* = 0.7143) based on summarized receiver operating characteristic (SROC) curves constructed using GEO datasets. Based on the in-house RT-qPCR, miR-198-5p expression was 4.3826 ± 1.7660 in LUSC tissues and 4.4522 ± 1.8263 in adjacent normal tissues (P = 0.885). The expression of miR-198-5p was significantly higher in patients with early TNM stages (I-II) than that in cases with advanced TNM stages (III-IV) (5.4400 ± 1.5277 vs 3.5690 ± 1.5228, P = 0.008). Continuous variable-based meta-analysis of GEO and PCR data displayed the SMD values of − 0.26 (95% CI − 0.48, − 0.04) and − 0.34 (95% CI − 0.71, 0.04) based on fixed and random effect models, respectively. As for the diagnostic value of miR-198-5p, the AUC based on the SROC curve using GEO and PCR data was 0.7351 (Q* = 0.6812). In total, 542 genes were identified as the targets of miR-198-5p. The most enriched Gene Ontology terms were epidermis development among biological processes, cell junction among cellular components, and protein dimerization activity among molecule functions. The pathway of non-small cell lung cancer was the most significant pathway identified using Kyoto Encyclopedia of Genes and Genomes analysis.

Conclusion

The expression of miR-198-5p is related to the TNM stage. Thus, miR-198-5p might play an important role via its target genes in LUSC.
Abkürzungen
LUSC
Lung squamous cell carcinoma
GEO
Gene Expression Omnibus
FFPE
Formalin-fixed, paraffin-embedded
mRNA
Messenger RNA
miRNA
Micro RNA
TCGA
The Cancer Genome Atlas
AUC
Area under the curve
SROC
Summarized receiver operating characteristic
NSCLC
Non-small cell lung cancer
GO
Gene Ontology
KEGG
Kyoto Encyclopedia of Genes and Genomes
BP
Biological processes
CC
Cellular components
MF
Molecular functions
PPI
Protein-protein interaction

Background

Lung cancer ranks first among all cancers in terms of incidence, and it is also the most important cause of cancer death all over the world [1]. Non-small cell lung cancer (NSCLC) accounts for around 85% of all lung cancers, with 30% of NSCLC cases being classified as lung squamous cell carcinoma (LUSC) [27]. Many patients are diagnosed with NSCLC at an advanced phase, which is attributable for the high mortality [8]. Therefore, more effective biomarkers are urgently needed in LUSC.
MicroRNAs (miRNAs) are ∼ 22-nt long endogenous RNAs that play significant roles in various cellular processes [9]. Previous studies have shown that miRNAs can target mRNAs involved in most of the developmental processes and are thus associating with many diseases [10]. Moreover, miRNAs have also been found to be involved in cancer [11]. Studies have found that miR-198-5p plays a vital role in many human cancers, including lung cancer [12]. A previous study [12] investigated the relationship between FGFR1 and miR-198-5p. However, the expression pattern of miR-198-5p in LUSC remains unknown. Additionally, the prospective target genes of miR-198-5p in LUSC have not yet been identified. Therefore, the relationship between miR-198-5p and lung squamous cell carcinoma as well as the underlying mechanism remains unknown.
To evaluate the clinical significance of miR-198-5p in LUSC, we examined miR-198-5p expression in LUSC tissues and carried out additional specific analyses to uncover its clinicopathological role. Furthermore, we performed big data analysis based on the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA). Subsequently, bioinformatics examinations were conducted to investigate the probable mechanism of miR-198-5p in LUSC.

Methods

Retrieval of data and publications from TCGA and GEO

The flowchart representing the main design of our study is shown in Fig. 1. We downloaded miRNA expression data from the Cancer Genome Atlas (TCGA) associated with LUSC. All data were converted to a log2 scale. We also retrieved data from the Gene Expression Omnibus (GEO) and ArrayExpress to assess the expression pattern of miR-198-5p in LUSC and corresponding non-tumor samples. The search terms were as follows: (“lung” OR “pulmonary” OR “respiratory” OR “bronchioles” OR “bronchi” OR “alveoli” OR “pneumocytes” OR “air way” [MeSH]) AND (“cancer” OR “carcinoma” OR “tumor” OR “neoplas” OR “malignan” “squamous cell carcinoma” OR “adenocarcinoma” [MeSH]) OR/AND (“MicroRNA” OR “miRNA” OR “MicroRNA” OR “Small Temporal RNA” OR “noncoding RNA” OR “ncRNA” OR “small RNA” [MeSH]). Datasets with expression levels of miR-198-5p in LUSC and corresponding non-tumor samples were included. Other types of tumor or other miRNA were excluded. The number of samples in the tumor and non-tumor groups was at least three. The expression level of miR-198-5p in the datasets was converted to a log2 scale. The number, mean, and standard deviation of miR-198-5p levels in the tumor and non-tumor groups were calculated. We also searched PubMed, Web of Science, Science Direct, Google Scholar, Ovid, LILACS, Wiley Online Library, EMBASE, Cochrane Central Register of Controlled Trials, Chong Qing VIP, CNKI, Wan Fang, and China Biology Medicine disc; however, no publications regarding miR-198-5p expression in LUSC were found in these databases.

RT-qPCR

After the formalin-fixed, paraffin-embedded (FFPE) sections were dewaxed, total RNA was achieved from these sections with the miRNeasy FFPE Kit (QIAGEN) according to manufacturer’s instruction. The concentration of RNA was measured using Nanodrop 2000. MiR-191 (CAACGGAAUCCCAAAAGCAGCU) and miR-103 (AGCAGCAUUGUACAGGGCUAUGA) were used as stably expressed control miRNAs as previously reported [13]. Applied Biosystems 7900 PCR system was used to perform real-time quantitative PCR and detect miR-198-5p expression (GGUCCAGAGGGGAGAUAGGUUC). The relative expression of miR-198-5p was calculated using the formula 2−ΔCq.

Statistical analysis

Paired sample t test and independent sample t test were performed using SPSS 23.0 to determine the association between miR-198-5p expression and various clinicopathological parameters based on real-time RT-qPCR and microarray data. P < 0.05 was regarded as being statistically significant. Receiver operating characteristic (ROC) curves were constructed using SPSS 23.0.
Concerning the meta-analysis based on all accessible data, we used Stata 14 to determine the combined expression value of miR-198-5p in tumor and non-tumor groups and its relationship with both standard mean difference (SMD) and summarized receiver operating characteristic (SROC). The fixed effect model was initially used. The random effect model was used when heterogeneity was detected. The data were considered heterogeneous when I2 > 50%. Subgroup analysis and sensitivity analysis were carried out to find out the source of heterogeneity. We tested publication bias with funnel plots. SPSS 23.0 was employed to explore the diagnostic value of miR-198-5p in LUSC based on GEO data. Then, we performed a diagnostic meta-analysis using MetaDiSc 1.4. Meta-regression and threshold effect analysis were performed to determine the source of heterogeneity. The data from TCGA were not included in the analysis because of missing data.

Differentially expressed mRNAs in LUSC based on TCGA

The expression level of each mRNA transformed into the log2 scale was evaluated using DESeq R package. We obtained 9860 differentially expressed genes in LUSC, including 6092 upregulated and 3768 downregulated genes.

Selection of putative target genes of miR-198-5p

Predictions were conducted in silico with miRWalk 2.0 (http://​zmf.​umm.​uni-heidelberg.​de/​apps/​zmf/​mirwalk2/​). Genes that were present in more than 5 of the 12 prediction online tools were selected for further analysis. The selected genes were cross-referenced with the differentially expressed genes in TCGA. The overlapping genes were considered the putative targets of miR-198-5p in LUSC.

Bioinformatics analyses

Gene Ontology (GO) annotation via DAVID (https://​david.​ncifcrf.​gov/​) was performed, including biological processes (BP), cellular components (CC), and molecular functions (MF). The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways associated with the putative target genes were also analyzed in DAVID. The results of GO annotation and KEGG pathway analysis were visualized using BiNGO and EnrichmentMap plugins in Cytoscape version 3.5.0. We used STRING (https://​string-db.​org/) to build interaction maps of the proteins encoded by the putative target genes.

Validation of the putative target genes in the most significant KEGG pathway based on TCGA data

We selected the genes in the most significant KEGG pathway “non-small cell lung cancer” for further analysis. The differences in the expression levels of E2F2, E2F3, TGFA, PRKCG, CDK6, EGF, and CDK4 between LUSC and non-tumor tissues were analyzed based on TCGA data.

Results

GEO data mining to determine the expression and diagnostic value of miR-198-5p

Considering the meta-analysis of miR-198-5p expression-based GEO data, eight datasets were included in our study. The scatter plots based on the GEO datasets are shown in Fig. 2. Forest plots using both fixed effect model (Fig. 3a) and random effect model (Fig. 3b) represented the expression level of miR-198-5p in LUSC. The combined effect sizes were − 0.30 (95% CI − 0.54, − 0.06) and − 0.39 (95% CI − 0.83, 0.05) based on the fixed and random effect models, respectively. Subgroup analysis showed that there was no heterogeneity among the studies from Asia (I2 = 0.0%) (Fig. 3c). The corresponding funnel plot is shown in Fig. 4a (P > 0.05). Sensitivity analysis (Fig. 4b) showed that the dataset GSE40738 might be a source of heterogeneity. The forest plot after the removal of GSE40738 is shown in Fig. 4c. The adjusted combined SMD value was − 0.56 (95% CI − 0.86, − 0.27) with I2 = 33.1%. The receiver operating characteristic curves based on the included datasets from GEO database are shown in Fig. 5. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 0.47 (95% CI 0.40, 0.54), 0.76 (95% CI 0.69, 0.82), 2.19 (95% CI 1.58, 3.05), 0.57 (95% CI 0.38, 0.84), and 4.64 (95% CI 2.04, 10.56), respectively (Fig. 6). The area under the curve (AUC) based on the summarized receiver operating characteristic (SROC) curve was 0.7749 (Q* = 0.7143) (Fig. 7). We did not find a threshold effect of miR-198-5p in the study (P = 0.058). Only study region was determined to be a covariant in the meta-regression, and thus it was likely not a source of heterogeneity (P = 0.0550) (Table 1).
Table 1
Meta-regression based on GEO data
Var
Coeff.
Std. Err.
P value
RDOR
[95% CI]
Cte.
0.123
0.782
0.8816
S
0.5
0.2152
0.0679
Region
1.221
0.4899
0.055
3.39
(0.96;11.95)

Clinical value of miR-198-5p in LUSC assessed using RT-qPCR

Using RT-qPCR, the expression of miR-198-5p in the LUSC tissues was (4.3826 ± 1.7660) compared with that in the non-tumor tissues (4.4522 ± 1.8263, P = 0.885) (Fig. 8a, b). The other clinicopathological features of the LUSC case are shown in Table 2. Notably, the expression level of miR-198-5p in patients with early TNM stage (I-II) was (5.4400 ± 1.5277) compared to (3.5690 ± 1.5228) in patients with advanced TNM stage (III-IV) (P = 0.008) (Fig. 8c, d).
Table 2
Relationship between the expression of miR-198-5p and clinicopathological features in LUSC patients
Clinicopathological feature
n
miR-198-5p expression (2−ΔCq)
Mean ± SD
t
P
Tissue
LUSC
23
4.3826 ± 1.7660
0.146
0.885
 
Non-tumor
23
4.4522 ± 1.8263
  
Gender
Male
18
4.4670 ± 1.8711
0.425
0.675
 
Female
5
4.0800 ± 1.4584
  
Age
< 60
15
4.0930 ± 1.4270
− 1.080
0.293
 
≥ 60
8
4.9250 ± 2.2833
  
Smoking state
No
12
4.3000 ± 1.2884
− 0.229
0.821
 
Yes
11
4.4730 ± 2.2401
  
Size
≤ 3 cm
7
4.2570 ± 2.1196
− 0.220
0.828
 
> 3 cm
16
4.4380 ± 1.6633
  
EGFR amplification
No
17
4.7470 ± 1.8084
1.741
0.096
 
Yes
6
3.3500 ± 1.2357
  
Vascular invasion
No
20
4.6100 ± 1.6914
1.656
0.113
 
Yes
3
2.8670 ± 1.7786
  
TNM stage
I-II
10
5.4400 ± 1.5277
2.917
0.008
 
III-IV
13
3.5690 ± 1.5228
  
LNM
No
11
4.8730 ± 2.0553
1.294
0.210
 
Yes
12
3.9330 ± 1.3918
  
EGFR protein
Low
18
4.3280 ± 1.9013
− 0.277
0.785
 
High
5
4.5800 ± 1.3142
  
MET
Low
13
4.9230 ± 1.6559
1.750
0.095
 
High
10
3.6800 ± 1.7313
  
Grading
II
16
4.4130 ± 1.8326
0.12
0.906
 
III
7
4.3140 ± 1.7411
  

Meta-analysis of miR-198-5p expression based on PCR and GEO data

The combined SMD values based on GEO and PCR data were − 0.26 (95% CI − 0.48, − 0.04) (Fig. 9a) and − 0.34 (95% CI − 0.71, 0.04) (Fig. 9b) using the fixed and random effect models, respectively. In subgroup analysis, no heterogeneity among the studies from Asia was observed (I2 = 0.0%) (Fig. 9c). The corresponding funnel plot is shown in Fig. 10a (P > 0.05). Once again, study region and the dataset GSE40738 were identified as sources of heterogeneity (Fig. 10b). After eliminating GSE40738 from the analysis, the SMD changed to − 0.46 (95% CI − 0.72, − 0.20) (Fig. 10c). The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 0.52 (95% CI 0.45, 0.58), 0.70 (95% CI 0.63, 0.76), 1.97 (95% CI 1.25, 3.13), 0.56 (95% CI 0.38, 0.82), and 4.23 (95% CI 2.07, 8.64), respectively (Fig. 11). The area under the curve (AUC) based on the summarized receiver operating characteristic (SROC) curve was 0.7351 (Q* = 0.6812) (Fig. 12). We also observed threshold effect of miR-198-5p in this study (P = 0.013). In this case, study region was not accountable for heterogeneity (P = 0.2107) (Table 3).
Table 3
Meta-regression based on GEO and in-house RT-qPCR data
Var
Coeff.
Std. Err.
P value
RDOR
[95%CI]
Cte.
0.27
0.9327
0.7816
S
0.125
0.1632
0.4714
Region
0.751
0.5363
0.2107
2.12
(0.57;7.88)

Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotation, and protein-protein interaction (PPI) network

In total, 542 genes were considered putative targets of miR-198-5p in LUSC (Fig. 13). Based on Gene Ontology (GO) analysis, the putative target genes of miR-198-5p were predominantly related to epidermis development with respect to biological processes (P = 4.84E−04) (Fig. 14, Table 4), cell junction in the case of cellular components (P = 7.60E−05) (Fig. 15, Table 4), and protein dimerization activity regarding molecular functions (P = 8.03E−05) (Fig. 16, Table 4). In terms of the KEGG pathway, the putative target genes of miR-198-5p were associated with non-small cell lung cancer, pathways in cancer and pancreatic cancer (Fig. 17, Table 5). The protein-protein interaction (PPI) network is shown in Fig. 18. The seven chosen genes in the KEGG pathway “non-small cell lung cancer” were all significantly upregulated in the LUSC samples compared to the non-tumor samples based on TCGA data (Fig. 19, Fig. 20).
Table 4
The most enriched 10 Gene Ontology (GO) term in biological process (BP) analysis, cellular component (CC), and molecular functions (MF)
Category
Term
Count
P value
GOTERM_BP_DIRECT
GO:0008544~epidermis development
10
4.84E−04
GOTERM_BP_DIRECT
GO:0043524~negative regulation of neuron apoptotic process
12
9.35E−04
GOTERM_BP_DIRECT
GO:0008284~positive regulation of cell proliferation
26
9.70E−04
GOTERM_BP_DIRECT
GO:0060070~canonical Wnt signaling pathway
9
0.001824
GOTERM_BP_DIRECT
GO:0007399~nervous system development
18
0.002211
GOTERM_BP_DIRECT
GO:0071277~cellular response to calcium ion
7
0.002457
GOTERM_BP_DIRECT
GO:0007269~neurotransmitter secretion
7
0.002457
GOTERM_BP_DIRECT
GO:0090103~cochlea morphogenesis
5
0.002641
GOTERM_BP_DIRECT
GO:0014075~response to amine
4
0.002773
GOTERM_BP_DIRECT
GO:0006366~transcription from RNA polymerase II promoter
26
0.003531
GOTERM_CC_DIRECT
GO:0030054~cell junction
29
7.60E−05
GOTERM_CC_DIRECT
GO:0005667~transcription factor complex
15
9.32E−04
GOTERM_CC_DIRECT
GO:0008021~synaptic vesicle
10
9.61E−04
GOTERM_CC_DIRECT
GO:0009986~cell surface
29
0.001109
GOTERM_CC_DIRECT
GO:0045202~synapse
13
0.004398
GOTERM_CC_DIRECT
GO:0005876~spindle microtubule
6
0.006912
GOTERM_CC_DIRECT
GO:0042734~presynaptic membrane
7
0.007013
GOTERM_CC_DIRECT
GO:0043195~terminal bouton
7
0.007013
GOTERM_CC_DIRECT
GO:0098793~presynapse
7
0.008171
GOTERM_CC_DIRECT
GO:0005887~integral component of plasma membrane
55
0.008929
GOTERM_MF_DIRECT
GO:0046983~protein dimerization activity
15
8.03E−05
GOTERM_MF_DIRECT
GO:0005509~calcium ion binding
36
9.88E−04
GOTERM_MF_DIRECT
GO:0016810~hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds
4
0.00922
GOTERM_MF_DIRECT
GO:0005109~frizzled binding
5
0.017408
GOTERM_MF_DIRECT
GO:0001105~RNA polymerase II transcription coactivator activity
5
0.019099
GOTERM_MF_DIRECT
GO:0043565~sequence-specific DNA binding
24
0.019304
GOTERM_MF_DIRECT
GO:0008080~N-acetyltransferase activity
4
0.022413
GOTERM_MF_DIRECT
GO:0003682~chromatin binding
19
0.026956
GOTERM_MF_DIRECT
GO:0001077~transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
13
0.033582
GOTERM_MF_DIRECT
GO:0005262~calcium channel activity
6
0.045673
Table 5
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotation of the putative target genes of miR-198-5p
Category
Term
Count
P value
KEGG_PATHWAY
hsa05223:Non-small cell lung cancer
7
0.002996
KEGG_PATHWAY
hsa05200:Pathways in cancer
20
0.005776
KEGG_PATHWAY
hsa05212:Pancreatic cancer
7
0.006302
KEGG_PATHWAY
hsa05214:Glioma
7
0.006302
KEGG_PATHWAY
hsa04512:ECM-receptor interaction
8
0.00691
KEGG_PATHWAY
hsa04151:PI3K-Akt signaling pathway
17
0.015931
KEGG_PATHWAY
hsa04360:Axon guidance
9
0.016478
KEGG_PATHWAY
hsa05219:Bladder cancer
5
0.020529
KEGG_PATHWAY
hsa05222:Small cell lung cancer
7
0.021937
KEGG_PATHWAY
hsa04550:Signaling pathways regulating pluripotency of stem cells
9
0.027765
KEGG_PATHWAY
hsa05166:HTLV-I infection
13
0.032302
KEGG_PATHWAY
hsa05218:Melanoma
6
0.035606
KEGG_PATHWAY
hsa00230:Purine metabolism
10
0.037636
KEGG_PATHWAY
hsa04390:Hippo signaling pathway
9
0.040805
KEGG_PATHWAY
hsa03410:Base excision repair
4
0.05213
KEGG_PATHWAY
hsa00250:Alanine, aspartate and glutamate metabolism
4
0.060271
KEGG_PATHWAY
hsa05206:MicroRNAs in cancer
13
0.063619
KEGG_PATHWAY
hsa04014:Ras signaling pathway
11
0.066327
KEGG_PATHWAY
hsa04724:Glutamatergic synapse
7
0.073405
KEGG_PATHWAY
hsa05230:Central carbon metabolism in cancer
5
0.082196
KEGG_PATHWAY
hsa05033:Nicotine addiction
4
0.083009
KEGG_PATHWAY
hsa04510:Focal adhesion
10
0.084102

Discussion

MiR-198-5p was clearly under-expressed in LUSC tissues in comparison with non-cancer lung tissues. The cases with LUSC in Asia expressed lower levels of miR-198-5p than did the healthy controls; however, the expression pattern in other regions was unclear. Our RT-qPCR indicated that the expression of miR-198-5p might be related to the tumor TNM stage, which suggests that miR-198-5p likely plays a role in tumor growth, lymph node metastasis, or distant metastasis. However, the downregulation of miR-198-5p was not obvious in our in-house RT-qPCR analysis. The diagnostic validation and meta-analysis based on GEO and RT-qPCR data indicated that miR-198-5p might be a biomarker of LUSC, but the sensitivity and specificity were not sufficiently high. Similarly, study region may be a source of heterogeneity, which suggested that the diagnostic screening might be suitable for Asian populations but not for others. Apart from LUSC, several studies have explored the expression pattern and mechanism of miR-198-5p in other diseases. MiR-198-5p has been reported to be upregulated in multiple myeloma [14], chronic pancreatitis or pancreatic ductal adenocarcinoma [15], Parkinson’s disease [16], esophageal cancer [17], preeclampsia [18], pancreatic adenocarcinoma, ampullary adenocarcinoma [19], lupus nephritis [20], retinoblastoma [21], anencephaly [22], and squamous cell carcinoma of tongue [23]. On the other hand, low expression of miR-198-5p has been found in prostate cancer [24], breast cancer [25], glioblastoma [26, 27], hepatocellular carcinoma [28], especially hepatitis C virus-associated hepatocellular carcinoma [29, 30], osteosarcoma [31], gastric cancer [32], colorectal cancer [33], pancreatic cancer [34], and respiratory syncytial virus (RSV) infection [35]. The overexpression of miR-198-5p has also been documented in CD8+ T cells in renal cell carcinoma [36]. In prostate cancer, a recent study indicated that miR-198-5p is targeted by the long noncoding RNA SChLAP1, leading to the activation of the MAPK1 pathway, thereby promoting cancer cell proliferation and metastasis [24]. Another study suggested that miR-198-5p may be involved in prostate cancer [37]. In hepatocellular carcinoma, miR-198-5p has been shown to target the HGF/c-MET pathway [38]. Several studies have revealed that the expression of miR-198-5p is greatly related to lymph node metastasis or distant metastasis in different malignant diseases, such as breast cancer [25], osteosarcoma [31], gastric cancer [32], and colorectal cancer [33]. Some studies have also shown that miR-198-5p is closely related to cell proliferation, apoptosis, and migration [12, 14, 39, 40]. The relationship between miR-198-5p and cancer prognosis is controversial [15, 17, 27, 3234]. Thus, we investigated whether miR-198-5p plays an important role in biological processes in various diseases, both malignant and benign.
In the case of lung adenocarcinoma, two reports have verified that miR-198-5p is under-expressed [12, 41]. However, studies on the characteristic of miR-198-5p in LUSC are lacking. One study assessed the diagnostic significance of miR-198-5p in lung adenocarcinoma, with sensitivity = 71.1%, specificity = 95.2%, and AUC = 0.887 (95% CI 0.801, 0.945) [41]. Our study highlighted the diagnostic value of miR-198-5p in LUSC. Yang et al. showed that miR-198-5p was capable to suppress proliferation and promote apoptosis in lung cancer cells by targeting FGFR1 [12], and Wu et al. showed that miR-198-5p promotes apoptosis, represses cell proliferation, and leads to cell cycle arrest in lung adenocarcinoma cells by directly targeting SHMT1 [39]. Our study showed that expression pattern and diagnostic value of miR-198-5p varied according to the race of the patient population, which should be further validated in larger samples.
Although many studies use prediction tools to determine miRNA target genes, the inadequate number of available prediction tools can lead to unreliable data. We used 12 online prediction tools based on miRWalk 2.0, and this method had not been previously utilized in LUSC. The predicted genes were cross-referenced with the differentially expressed genes in TCGA, which further enhanced the specificity and accuracy of our investigation. Because miR-198-5p is downregulated in LUSC, we chose the upregulated genes from TCGA. Via bioinformatics analyses, the putative target genes of miR-198-5p were most significantly enriched in the KEGG pathways of non-small cell lung cancer, pathways in cancer, pancreatic cancer, glioma, and ECM-receptor interactions. For the GO biological processes, the putative target genes of miR-198-5p were involved in epidermis development, negative regulation of neuron apoptotic processes, positive regulation of cell proliferation, the canonical Wnt signaling pathway, and nervous system development, which indicated that the putative target genes might regulated epidermis proliferation, cell apoptosis, or carcinoma of nervous tissues. In addition, for the GO cellular components, the putative target genes of miR-198-5p were enriched in cell junction, transcription factor complex, synaptic vesicle, cell surface proteins, and synapses, which are related to migration, metastasis, and intercellular exchange of molecules. In terms of the GO molecular functions, the putative target genes of miR-198-5p were associated with protein dimerization activity, calcium ion binding, hydrolase activity on carbon-nitrogen (but not peptide) bonds, frizzled binding, and RNA polymerase II transcription co-activator activity. To verify the accuracy of our analysis, we selected several genes and determined its expression based on TCGA. The genes included the pathway non-small cell lung cancer were E2F2, E2F3, TGFA, PRKCG, CDK6, EGF, and CDK4, which were all expressed at significantly higher levels in LUSC tissues in comparison to that in the non-cancer group. Thus, these genes are probably the targets of miR-198-5p. The putative target genes of miR-198 should be validated further in the future.

Conclusions

MiR-198-5p might be downregulated in LUSC, especially in Asia region. The putative target genes of miR-198-5p were closely related to tumorigenesis and progress in LUSC.

Acknowledgements

None.

Funding

Open fund of Guangxi Colleges and Universities Key Laboratory of Biological Molecular Medicine Research (GXBMR201601), the Youth Science Foundation of Guangxi Medical University (GXMUYSF2014032), and Future Academic Star of Guangxi Medical University (WLXSZX17001) funded this study.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.
This study was approved by the Medical Ethics Committee of First Affiliated Hospital of Guangxi Medical University (Approval Number: 2015 (KY-E-041)), and written informed consent was also obtained from each participant.
Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed
2.
Zurück zum Zitat An HJ, Lee YJ, Hong SA, Kim JO, Lee KY, Kim YK, Park JK, Kang JH. The prognostic role of tissue and serum MMP-1 and TIMP-1 expression in patients with non-small cell lung cancer. Pathol Res Pract. 2016;212:357–64.CrossRefPubMed An HJ, Lee YJ, Hong SA, Kim JO, Lee KY, Kim YK, Park JK, Kang JH. The prognostic role of tissue and serum MMP-1 and TIMP-1 expression in patients with non-small cell lung cancer. Pathol Res Pract. 2016;212:357–64.CrossRefPubMed
3.
Zurück zum Zitat Siegfried JM, Lin Y, Diergaarde B, Lin HM, Dacic S, Pennathur A, Weissfeld JL, Romkes M, Nukui T, Stabile LP. Expression of PAM50 genes in lung cancer: evidence that interactions between hormone receptors and HER2/HER3 contribute to poor outcome. Neoplasia. 2015;17:817–25.CrossRefPubMedPubMedCentral Siegfried JM, Lin Y, Diergaarde B, Lin HM, Dacic S, Pennathur A, Weissfeld JL, Romkes M, Nukui T, Stabile LP. Expression of PAM50 genes in lung cancer: evidence that interactions between hormone receptors and HER2/HER3 contribute to poor outcome. Neoplasia. 2015;17:817–25.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Tajima S, Takanashi Y, Koda K. Squamous cell carcinoma of the lung with highly proliferating fibromatosis-like stroma: a rare phenomenon. Int J Clin Exp Pathol. 2015;8:5870–6.PubMedPubMedCentral Tajima S, Takanashi Y, Koda K. Squamous cell carcinoma of the lung with highly proliferating fibromatosis-like stroma: a rare phenomenon. Int J Clin Exp Pathol. 2015;8:5870–6.PubMedPubMedCentral
5.
Zurück zum Zitat Chiang Y, Yang JC, Hsu FM, Chen YH, Shih JY, Lin ZZ, Lan KH, Cheng AL, Kuo SH. The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases. PLoS One. 2015;10:e0145936.CrossRefPubMedPubMedCentral Chiang Y, Yang JC, Hsu FM, Chen YH, Shih JY, Lin ZZ, Lan KH, Cheng AL, Kuo SH. The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases. PLoS One. 2015;10:e0145936.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Lee E, Jin D, Lee BB, Kim Y, Han J, Shim YM, Kim DH. Negative effect of cyclin D1 overexpression on recurrence-free survival in stage II-IIIA lung adenocarcinoma and its expression modulation by vorinostat in vitro. BMC Cancer. 2015;15:982.CrossRefPubMedPubMedCentral Lee E, Jin D, Lee BB, Kim Y, Han J, Shim YM, Kim DH. Negative effect of cyclin D1 overexpression on recurrence-free survival in stage II-IIIA lung adenocarcinoma and its expression modulation by vorinostat in vitro. BMC Cancer. 2015;15:982.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Lin SY, Peng F. Association of SIRT1 and HMGA1 expression in non-small cell lung cancer. Oncol Lett. 2016;11:782–8.CrossRefPubMed Lin SY, Peng F. Association of SIRT1 and HMGA1 expression in non-small cell lung cancer. Oncol Lett. 2016;11:782–8.CrossRefPubMed
8.
Zurück zum Zitat Ming F, Sun Q. Epigenetically silenced PTPRO functions as a prognostic marker and tumor suppressor in human lung squamous cell carcinoma. Mol Med Rep. 2017;16:746–54.CrossRefPubMedPubMedCentral Ming F, Sun Q. Epigenetically silenced PTPRO functions as a prognostic marker and tumor suppressor in human lung squamous cell carcinoma. Mol Med Rep. 2017;16:746–54.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefPubMed Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefPubMed
10.
Zurück zum Zitat Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010;42:1273–81.CrossRefPubMed Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010;42:1273–81.CrossRefPubMed
11.
Zurück zum Zitat Dou Z, Lin S, Dai C, Lu Y, Tian T, Wang M, Liu X, Zheng Y, Xu P, Li S, et al. Pooling-analysis for diagnostic and prognostic value of MiRNA-100 in various cancers. Oncotarget. 2017;8:62703–15.PubMedPubMedCentral Dou Z, Lin S, Dai C, Lu Y, Tian T, Wang M, Liu X, Zheng Y, Xu P, Li S, et al. Pooling-analysis for diagnostic and prognostic value of MiRNA-100 in various cancers. Oncotarget. 2017;8:62703–15.PubMedPubMedCentral
12.
Zurück zum Zitat Yang J, Zhao H, Xin Y, Fan L. MicroRNA-198 inhibits proliferation and induces apoptosis of lung cancer cells via targeting FGFR1. J Cell Biochem. 2014;115:987–95.CrossRefPubMed Yang J, Zhao H, Xin Y, Fan L. MicroRNA-198 inhibits proliferation and induces apoptosis of lung cancer cells via targeting FGFR1. J Cell Biochem. 2014;115:987–95.CrossRefPubMed
13.
Zurück zum Zitat Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA. 2008;14:844–52.CrossRefPubMedPubMedCentral Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA. 2008;14:844–52.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Bi C, Chung TH, Huang G, Zhou J, Yan J, Ahmann GJ, Fonseca R, Chng WJ. Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma. Oncotarget. 2015;6:26508–18.PubMedPubMedCentral Bi C, Chung TH, Huang G, Zhou J, Yan J, Ahmann GJ, Fonseca R, Chng WJ. Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma. Oncotarget. 2015;6:26508–18.PubMedPubMedCentral
15.
Zurück zum Zitat Vychytilova-Faltejskova P, Kiss I, Klusova S, Hlavsa J, Prochazka V, Kala Z, Mazanec J, Hausnerova J, Kren L, Hermanova M, et al. MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma. Diagn Pathol. 2015;10:38.CrossRefPubMedPubMedCentral Vychytilova-Faltejskova P, Kiss I, Klusova S, Hlavsa J, Prochazka V, Kala Z, Mazanec J, Hausnerova J, Kren L, Hermanova M, et al. MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma. Diagn Pathol. 2015;10:38.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Cardo LF, Coto E, Ribacoba R, Menendez M, Moris G, Suarez E, Alvarez V. MiRNA profile in the substantia nigra of Parkinson’s disease and healthy subjects. J Mol Neurosci. 2014;54:830–6.CrossRefPubMed Cardo LF, Coto E, Ribacoba R, Menendez M, Moris G, Suarez E, Alvarez V. MiRNA profile in the substantia nigra of Parkinson’s disease and healthy subjects. J Mol Neurosci. 2014;54:830–6.CrossRefPubMed
17.
Zurück zum Zitat Qi B, Yao WJ, Zhao BS, Qin XG, Wang Y, Wang WJ, Wang TY, Liu SG, Li HC. Involvement of microRNA-198 overexpression in the poor prognosis of esophageal cancer. Asian Pac J Cancer Prev. 2013;14:5073–6.CrossRefPubMed Qi B, Yao WJ, Zhao BS, Qin XG, Wang Y, Wang WJ, Wang TY, Liu SG, Li HC. Involvement of microRNA-198 overexpression in the poor prognosis of esophageal cancer. Asian Pac J Cancer Prev. 2013;14:5073–6.CrossRefPubMed
18.
Zurück zum Zitat Choi SY, Yun J, Lee OJ, Han HS, Yeo MK, Lee MA, Suh KS. MicroRNA expression profiles in placenta with severe preeclampsia using a PNA-based microarray. Placenta. 2013;34:799–804.CrossRefPubMed Choi SY, Yun J, Lee OJ, Han HS, Yeo MK, Lee MA, Suh KS. MicroRNA expression profiles in placenta with severe preeclampsia using a PNA-based microarray. Placenta. 2013;34:799–804.CrossRefPubMed
19.
Zurück zum Zitat Schultz NA, Werner J, Willenbrock H, Roslind A, Giese N, Horn T, Wojdemann M, Johansen JS. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Mod Pathol. 2012;25:1609–22.CrossRefPubMed Schultz NA, Werner J, Willenbrock H, Roslind A, Giese N, Horn T, Wojdemann M, Johansen JS. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Mod Pathol. 2012;25:1609–22.CrossRefPubMed
20.
Zurück zum Zitat Lu J, Kwan BC, Lai FM, Tam LS, Li EK, Chow KM, Wang G, Li PK, Szeto CC. Glomerular and tubulointerstitial miR-638, miR-198 and miR-146a expression in lupus nephritis. Nephrology (Carlton). 2012;17:346–51.CrossRef Lu J, Kwan BC, Lai FM, Tam LS, Li EK, Chow KM, Wang G, Li PK, Szeto CC. Glomerular and tubulointerstitial miR-638, miR-198 and miR-146a expression in lupus nephritis. Nephrology (Carlton). 2012;17:346–51.CrossRef
21.
Zurück zum Zitat Zhao JJ, Yang J, Lin J, Yao N, Zhu Y, Zheng J, Xu J, Cheng JQ, Lin JY, Ma X. Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst. 2009;25:13–20.CrossRefPubMed Zhao JJ, Yang J, Lin J, Yao N, Zhu Y, Zheng J, Xu J, Cheng JQ, Lin JY, Ma X. Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst. 2009;25:13–20.CrossRefPubMed
22.
Zurück zum Zitat Zhang Z, Chang H, Li Y, Zhang T, Zou J, Zheng X, Wu J. MicroRNAs: potential regulators involved in human anencephaly. Int J Biochem Cell Biol. 2010;42:367–74.CrossRefPubMed Zhang Z, Chang H, Li Y, Zhang T, Zou J, Zheng X, Wu J. MicroRNAs: potential regulators involved in human anencephaly. Int J Biochem Cell Biol. 2010;42:367–74.CrossRefPubMed
23.
Zurück zum Zitat Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res. 2008;14:2588–92.CrossRefPubMed Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res. 2008;14:2588–92.CrossRefPubMed
24.
Zurück zum Zitat Li Y, Luo H, Xiao N, Duan J, Wang Z, Wang S. Long noncoding RNA SChLAP1 accelerates the proliferation and metastasis of prostate cancer via targeting miR-198 and promoting the MAPK1 pathway. Oncol Res. 2017; Li Y, Luo H, Xiao N, Duan J, Wang Z, Wang S. Long noncoding RNA SChLAP1 accelerates the proliferation and metastasis of prostate cancer via targeting miR-198 and promoting the MAPK1 pathway. Oncol Res. 2017;
25.
Zurück zum Zitat Hu Y, Tang Z, Jiang B, Chen J, Fu Z. miR-198 functions as a tumor suppressor in breast cancer by targeting CUB domain-containing protein 1. Oncol Lett. 2017;13:1753–60.CrossRefPubMedPubMedCentral Hu Y, Tang Z, Jiang B, Chen J, Fu Z. miR-198 functions as a tumor suppressor in breast cancer by targeting CUB domain-containing protein 1. Oncol Lett. 2017;13:1753–60.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Nie E, Jin X, Wu W, Yu T, Zhou X, Shi Z, Zhang J, Liu N, You Y. MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT. J Neuro-Oncol. 2017;133:59–68.CrossRef Nie E, Jin X, Wu W, Yu T, Zhou X, Shi Z, Zhang J, Liu N, You Y. MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT. J Neuro-Oncol. 2017;133:59–68.CrossRef
27.
Zurück zum Zitat Man HB, Bi WP, Man HH. Decreased microRNA-198 expression and its prognostic significance in human glioma. Genet Mol Res. 2016;15 Man HB, Bi WP, Man HH. Decreased microRNA-198 expression and its prognostic significance in human glioma. Genet Mol Res. 2016;15
28.
Zurück zum Zitat Huang WT, Wang HL, Yang H, Ren FH, Luo YH, Huang CQ, Liang YY, Liang HW, Chen G, Dang YW. Lower expressed miR-198 and its potential targets in hepatocellular carcinoma: a clinicopathological and in silico study. Onco Targets Ther. 2016;9:5163–80.CrossRefPubMedPubMedCentral Huang WT, Wang HL, Yang H, Ren FH, Luo YH, Huang CQ, Liang YY, Liang HW, Chen G, Dang YW. Lower expressed miR-198 and its potential targets in hepatocellular carcinoma: a clinicopathological and in silico study. Onco Targets Ther. 2016;9:5163–80.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Elfimova N, Sievers E, Eischeid H, Kwiecinski M, Noetel A, Hunt H, Becker D, Frommolt P, Quasdorff M, Steffen HM, et al. Control of mitogenic and motogenic pathways by miR-198, diminishing hepatoma cell growth and migration. Biochim Biophys Acta. 1833;2013:1190–8. Elfimova N, Sievers E, Eischeid H, Kwiecinski M, Noetel A, Hunt H, Becker D, Frommolt P, Quasdorff M, Steffen HM, et al. Control of mitogenic and motogenic pathways by miR-198, diminishing hepatoma cell growth and migration. Biochim Biophys Acta. 1833;2013:1190–8.
30.
Zurück zum Zitat Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, Odenthal M. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology. 2008;47:1223–32.CrossRefPubMed Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, Odenthal M. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology. 2008;47:1223–32.CrossRefPubMed
31.
Zurück zum Zitat Zhang S, Zhao Y, Wang L. MicroRNA-198 inhibited tumorous behaviors of human osteosarcoma through directly targeting ROCK1. Biochem Biophys Res Commun. 2016;472:557–65.CrossRefPubMed Zhang S, Zhao Y, Wang L. MicroRNA-198 inhibited tumorous behaviors of human osteosarcoma through directly targeting ROCK1. Biochem Biophys Res Commun. 2016;472:557–65.CrossRefPubMed
32.
33.
Zurück zum Zitat Wang M, Wang J, Kong X, Chen H, Wang Y, Qin M, Lin Y, Chen H, Xu J, Hong J, et al. MiR-198 represses tumor growth and metastasis in colorectal cancer by targeting fucosyl transferase 8. Sci Rep. 2014;4:6145.CrossRefPubMedPubMedCentral Wang M, Wang J, Kong X, Chen H, Wang Y, Qin M, Lin Y, Chen H, Xu J, Hong J, et al. MiR-198 represses tumor growth and metastasis in colorectal cancer by targeting fucosyl transferase 8. Sci Rep. 2014;4:6145.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Marin-Muller C, Li D, Bharadwaj U, Li M, Chen C, Hodges SE, Fisher WE, Mo Q, Hung MC, Yao Q. A tumorigenic factor interactome connected through tumor suppressor microRNA-198 in human pancreatic cancer. Clin Cancer Res. 2013;19:5901–13.CrossRefPubMedPubMedCentral Marin-Muller C, Li D, Bharadwaj U, Li M, Chen C, Hodges SE, Fisher WE, Mo Q, Hung MC, Yao Q. A tumorigenic factor interactome connected through tumor suppressor microRNA-198 in human pancreatic cancer. Clin Cancer Res. 2013;19:5901–13.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Bakre A, Mitchell P, Coleman JK, Jones LP, Saavedra G, Teng M, Tompkins SM, Tripp RA. Respiratory syncytial virus modifies microRNAs regulating host genes that affect virus replication. J Gen Virol. 2012;93:2346–56.CrossRefPubMedPubMedCentral Bakre A, Mitchell P, Coleman JK, Jones LP, Saavedra G, Teng M, Tompkins SM, Tripp RA. Respiratory syncytial virus modifies microRNAs regulating host genes that affect virus replication. J Gen Virol. 2012;93:2346–56.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Gigante M, Pontrelli P, Herr W, Gigante M, D'Avenia M, Zaza G, Cavalcanti E, Accetturo M, Lucarelli G, Carrieri G, et al. miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction. J Transl Med. 2016;14:84.CrossRefPubMedPubMedCentral Gigante M, Pontrelli P, Herr W, Gigante M, D'Avenia M, Zaza G, Cavalcanti E, Accetturo M, Lucarelli G, Carrieri G, et al. miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction. J Transl Med. 2016;14:84.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Ye L, Li S, Ye D, Yang D, Yue F, Guo Y, Chen X, Chen F, Zhang J, Song X. Livin expression may be regulated by miR-198 in human prostate cancer cell lines. Eur J Cancer. 2013;49:734–40.CrossRefPubMed Ye L, Li S, Ye D, Yang D, Yue F, Guo Y, Chen X, Chen F, Zhang J, Song X. Livin expression may be regulated by miR-198 in human prostate cancer cell lines. Eur J Cancer. 2013;49:734–40.CrossRefPubMed
38.
Zurück zum Zitat Tan S, Li R, Ding K, Lobie PE, Zhu T. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett. 2011;585:2229–34.CrossRefPubMed Tan S, Li R, Ding K, Lobie PE, Zhu T. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett. 2011;585:2229–34.CrossRefPubMed
39.
Zurück zum Zitat Wu S, Zhang G, Li P, Chen S, Zhang F, Li J, Jiang C, Chen X, Wang Y, Du Y, et al. miR-198 targets SHMT1 to inhibit cell proliferation and enhance cell apoptosis in lung adenocarcinoma. Tumour Biol. 2016;37:5193–202.CrossRefPubMed Wu S, Zhang G, Li P, Chen S, Zhang F, Li J, Jiang C, Chen X, Wang Y, Du Y, et al. miR-198 targets SHMT1 to inhibit cell proliferation and enhance cell apoptosis in lung adenocarcinoma. Tumour Biol. 2016;37:5193–202.CrossRefPubMed
40.
Zurück zum Zitat Wang J, Dan G, Shangguan T, Hao H, Tang R, Peng K, Zhao J, Sun H, Zou Z. miR-198 represses the proliferation of HaCaT cells by targeting cyclin D2. Int J Mol Sci. 2015;16:17018–28.CrossRefPubMedPubMedCentral Wang J, Dan G, Shangguan T, Hao H, Tang R, Peng K, Zhao J, Sun H, Zou Z. miR-198 represses the proliferation of HaCaT cells by targeting cyclin D2. Int J Mol Sci. 2015;16:17018–28.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Han HS, Yun J, Lim SN, Han JH, Lee KH, Kim ST, Kang MH, Son SM, Lee YM, Choi SY, et al. Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion. Int J Cancer. 2013;133:645–52.CrossRefPubMed Han HS, Yun J, Lim SN, Han JH, Lee KH, Kim ST, Kang MH, Son SM, Lee YM, Choi SY, et al. Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion. Int J Cancer. 2013;133:645–52.CrossRefPubMed
Metadaten
Titel
Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR
verfasst von
Yue-ya Liang
Jia-cheng Huang
Rui-xue Tang
Wen-jie Chen
Peng Chen
Wei-luan Cen
Ke Shi
Li Gao
Xiang Gao
An-gui Liu
Xiao-tong Peng
Gang Chen
Su-ning Huang
Ye-ying Fang
Yong-yao Gu
Publikationsdatum
01.12.2018
Verlag
BioMed Central
Erschienen in
World Journal of Surgical Oncology / Ausgabe 1/2018
Elektronische ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-018-1320-y

Weitere Artikel der Ausgabe 1/2018

World Journal of Surgical Oncology 1/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.